BCL2L1 and neoplasm: First, we treated liver cancer cell lines with regorafenib and the specific BCL-xL inhibitor A-1331852, a BH3-mimetic that greatly potentiates regorafenib anti-tumor activity, to verify if ROS production is modified during BH3-mimetic sensitization.